MAP2K1 and neoplasm: Bertotti et al35 recently carried out exome sequence and copy number analyses of both patient‐derived xenografts and patient tumours, to investigate the effects of mutations in ERBB2, EGFR, FGFR1, PDGFRA and MAP2K1 in relation to resistance to anti‐EGFR therapies.